This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Raguz, S. Articles by Yagüe, E. Search for Related Content PubMed PubMed Citation Articles by Raguz, S. Articles by Yagüe, E.

Activation of the MDR1 Upstream Promoter in Breast Carcinoma as a Surrogate for Metastatic Invasion

¹ Clinical Sciences Centre, Medical Research Council and
² Department of Cancer Medicine, Imperial College, Hammersmith Hospital, London, United Kingdom

Purpose: Activation of the MDR1 upstream promoter (USP) has been described previously in four lymphoblastic leukemia patients, where it is the major MDR1 promoter associated with P-glycoprotein overexpression. We asked whether MDR1 USP-derived transcripts were also present in breast carcinoma and assessed their potential as a biomarker.

Experimental Design: We developed a sensitive method for detecting transcripts derived from the MDR1 USP and used it to identify MDR1 USP-derived transcripts in cell model systems, in 61 breast carcinoma biopsies of the primary tumor, and in isolated malignant epithelial cells both from the primary tumor and from the associated invaded lymph nodes.

Results: The MDR1 USP was not active in several independent leukemic and breast cancer cell lines or nucleated peripheral blood cells (n = 9). However, transcripts derived from the MDR1 USP were detected in some drug-resistant cell lines and a high proportion of primary breast tumors (71.6%; n = 61), whereas they were present at low frequency in normal breast tissue (10%; n = 10). Activation of MDR1 USP was not due to chromosomal amplifications or rearrangements at the MDR1 locus. Transcription from the MDR1 USP correlated with metastatic node invasion [N = 0–3 versus N > 3 (N = number of lymph nodes invaded); Fisher’s exact test, P = 0.011] and was detected in malignant epithelial cells from the primary tumor and those that metastasized to the lymph nodes.

Conclusions: MDR1 USP activation is a surrogate marker for breast carcinoma progression and can be used as a marker to study breast cancer susceptibility.

This article has been cited by other articles:

				R. Callaghan, E. Crowley, S. Potter, and I. D. Kerr P-glycoprotein: So Many Ways to Turn It On J. Clin. Pharmacol., March 1, 2008; 48(3): 365 - 378. [Abstract] [Full Text] [PDF]

				A. Gomez-Martinez, P. Garcia-Morales, A. Carrato, M. D. Castro-Galache, J. L. Soto, E. Carrasco-Garcia, M. Garcia-Bautista, P. Guaraz, J. A. Ferragut, and M. Saceda Post-transcriptional Regulation of P-Glycoprotein Expression in Cancer Cell Lines Mol. Cancer Res., June 1, 2007; 5(6): 641 - 653. [Abstract] [Full Text] [PDF]

				E. Yague, A. Arance, L. Kubitza, M. O'Hare, P. Jat, C. M. Ogilvie, I. R. Hart, C. F. Higgins, and S. Raguz Ability to Acquire Drug Resistance Arises Early during the Tumorigenesis Process Cancer Res., February 1, 2007; 67(3): 1130 - 1137. [Abstract] [Full Text] [PDF]

				B. Wang, S. Ngoi, J. Wang, S. S. Chong, and C. G. L. Lee The Promoter Region of the MDR1 Gene Is Largely Invariant, but Different Single Nucleotide Polymorphism Haplotypes Affect MDR1 Promoter Activity Differently in Different Cell Lines Mol. Pharmacol., July 1, 2006; 70(1): 267 - 276. [Abstract] [Full Text] [PDF]

				K. E. Miletti-Gonzalez, S. Chen, N. Muthukumaran, G. N. Saglimbeni, X. Wu, J. Yang, K. Apolito, W. J. Shih, W. N. Hait, and L. Rodriguez-Rodriguez The CD44 Receptor Interacts with P-Glycoprotein to Promote Cell Migration and Invasion in Cancer Cancer Res., August 1, 2005; 65(15): 6660 - 6667. [Abstract] [Full Text] [PDF]